The discovery of genetic mapping led to a considerable expansion of medical data knowledge or ‘big data,’ which Foley partner Richard Kaufman suggests can be properly analyzed to improve drug discovery success and reduce the cost of developing a drug. He compares genetic mapping to an exquisite tailoring of one’s personal biology that holds the potential to make drugs developed using this data much more effective and ultimately may lead to better outcomes for patients.
People
Related News
June 20, 2025
In the News
Brian Wheeler and Lyman Thai Comment on Private Equity's Entry into Niche Sports
Foley & Lardner LLP partners Brian Wheeler and Lyman Thai described private equity's growing investments in niche sports in the Pensions & Investments article, "Ares Management buys minority stake in French sailing team."
June 16, 2025
In the News
Gregory Husisian on Customs Compliance Violations – 'It's a sharply increased risk profile'
Foley & Lardner LLP partner Gregory Husisian joined the SupplyChainBrain Thought Leaders episode, "Getting Ahead of Customs Compliance Violations," to describe the heightened risk environment importers face under the current trade and regulatory regime.
June 11, 2025
In the News
Foley Named Top US Firm for IP Lateral Hires by ManagingIP
Foley & Lardner LLP was named the top United States firm for intellectual property lateral partner hires in April and May 2025 based on data from ManagingIP's Talent Tracker.